China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) Stock Competitors & Peer Comparison
See SXTC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SXTC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SXTC | $3.39 | -3.42% | 1.8M | 1.18 | $2.80 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
SXTC vs TAK Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TAK's P/E ratio is 12.52. In terms of profitability, SXTC's ROE is -0.31%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SXTC is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TAK's competition here
Haleon plc (NYSE: HLN)
SXTC vs HLN Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas HLN's P/E ratio is 18.28. In terms of profitability, SXTC's ROE is -0.31%, compared to HLN's ROE of +0.17%. Regarding short-term risk, SXTC is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
SXTC vs TEVA Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TEVA's P/E ratio is 12.54. In terms of profitability, SXTC's ROE is -0.31%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, SXTC is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
SXTC vs VTRS Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas VTRS's P/E ratio is 6.39. In terms of profitability, SXTC's ROE is -0.31%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, SXTC is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
SXTC vs ITCI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SXTC's ROE is -0.31%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, SXTC is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
SXTC vs CTLT Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SXTC's ROE is -0.31%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SXTC is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
SXTC vs ELAN Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ELAN's P/E ratio is 20.91. In terms of profitability, SXTC's ROE is -0.31%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, SXTC is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
SXTC vs RDY Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas RDY's P/E ratio is 20.30. In terms of profitability, SXTC's ROE is -0.31%, compared to RDY's ROE of +0.09%. Regarding short-term risk, SXTC is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
SXTC vs LNTH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas LNTH's P/E ratio is 16.93. In terms of profitability, SXTC's ROE is -0.31%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, SXTC is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
SXTC vs AMRX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas AMRX's P/E ratio is 19.62. In terms of profitability, SXTC's ROE is -0.31%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, SXTC is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
SXTC vs INDV Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas INDV's P/E ratio is 10.61. In terms of profitability, SXTC's ROE is -0.31%, compared to INDV's ROE of -2.16%. Regarding short-term risk, SXTC is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
SXTC vs SUPN Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SUPN trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SUPN's P/E ratio is 15.64. In terms of profitability, SXTC's ROE is -0.31%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, SXTC is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
SXTC vs RGC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas RGC's P/E ratio is -356.34. In terms of profitability, SXTC's ROE is -0.31%, compared to RGC's ROE of -2.32%. Regarding short-term risk, SXTC is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
SXTC vs BHC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas BHC's P/E ratio is 1.58. In terms of profitability, SXTC's ROE is -0.31%, compared to BHC's ROE of +0.89%. Regarding short-term risk, SXTC is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
SXTC vs DCPH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SXTC's ROE is -0.31%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SXTC is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
SXTC vs HCM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas HCM's P/E ratio is 4.59. In terms of profitability, SXTC's ROE is -0.31%, compared to HCM's ROE of +0.01%. Regarding short-term risk, SXTC is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
SXTC vs AVDL Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SXTC's ROE is -0.31%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, SXTC is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
SXTC vs EMBCV Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SXTC's ROE is -0.31%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, SXTC is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
SXTC vs DVAX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SXTC's ROE is -0.31%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, SXTC is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
SXTC vs PRGO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PRGO's P/E ratio is 5.07. In terms of profitability, SXTC's ROE is -0.31%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, SXTC is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
SXTC vs ANIP Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ANIP's P/E ratio is 9.14. In terms of profitability, SXTC's ROE is -0.31%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, SXTC is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
SXTC vs TARO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TARO's P/E ratio is 30.05. In terms of profitability, SXTC's ROE is -0.31%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SXTC is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
SXTC vs HROW Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas HROW's P/E ratio is 437.33. In terms of profitability, SXTC's ROE is -0.31%, compared to HROW's ROE of -1.04%. Regarding short-term risk, SXTC is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
SXTC vs PAHC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PAHC's P/E ratio is 11.54. In terms of profitability, SXTC's ROE is -0.31%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, SXTC is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
SXTC vs ALVO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ALVO's P/E ratio is -11.79. In terms of profitability, SXTC's ROE is -0.31%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, SXTC is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
SXTC vs CRON Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CRON's P/E ratio is 30.10. In terms of profitability, SXTC's ROE is -0.31%, compared to CRON's ROE of +0.06%. Regarding short-term risk, SXTC is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
SXTC vs ETON Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ETON's P/E ratio is -594.00. In terms of profitability, SXTC's ROE is -0.31%, compared to ETON's ROE of -0.06%. Regarding short-term risk, SXTC is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
SXTC vs PCRX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PCRX's P/E ratio is 9.12. In terms of profitability, SXTC's ROE is -0.31%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, SXTC is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
SXTC vs PETQ Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SXTC's ROE is -0.31%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SXTC is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
SXTC vs AMPH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas AMPH's P/E ratio is 6.82. In terms of profitability, SXTC's ROE is -0.31%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, SXTC is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
SXTC vs COLL Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas COLL's P/E ratio is 3.26. In terms of profitability, SXTC's ROE is -0.31%, compared to COLL's ROE of +0.16%. Regarding short-term risk, SXTC is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
SXTC vs EVO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, EVO has a market cap of 778M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas EVO's P/E ratio is -3.09. In terms of profitability, SXTC's ROE is -0.31%, compared to EVO's ROE of -0.24%. Regarding short-term risk, SXTC is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
SXTC vs IRWD Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas IRWD's P/E ratio is 5.54. In terms of profitability, SXTC's ROE is -0.31%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, SXTC is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
SXTC vs BDSI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SXTC's ROE is -0.31%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SXTC is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
SXTC vs EOLS Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas EOLS's P/E ratio is -25.71. In terms of profitability, SXTC's ROE is -0.31%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, SXTC is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
SXTC vs AQST Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas AQST's P/E ratio is -6.93. In terms of profitability, SXTC's ROE is -0.31%, compared to AQST's ROE of +2.44%. Regarding short-term risk, SXTC is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
SXTC vs TLRY Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TLRY's P/E ratio is -4.32. In terms of profitability, SXTC's ROE is -0.31%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, SXTC is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
SXTC vs CGC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CGC's P/E ratio is -0.62. In terms of profitability, SXTC's ROE is -0.31%, compared to CGC's ROE of -0.33%. Regarding short-term risk, SXTC is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
SXTC vs KMDA Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas KMDA's P/E ratio is 19.66. In terms of profitability, SXTC's ROE is -0.31%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SXTC is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
SXTC vs TKNO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TKNO's P/E ratio is -23.84. In terms of profitability, SXTC's ROE is -0.31%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, SXTC is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
SXTC vs ALIM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SXTC's ROE is -0.31%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SXTC is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
SXTC vs EMBC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas EMBC's P/E ratio is 1.83. In terms of profitability, SXTC's ROE is -0.31%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, SXTC is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
SXTC vs LNDC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SXTC's ROE is -0.31%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, SXTC is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
SXTC vs ACB Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ACB's P/E ratio is -7.80. In terms of profitability, SXTC's ROE is -0.31%, compared to ACB's ROE of -0.21%. Regarding short-term risk, SXTC is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
SXTC vs ORGO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ORGO's P/E ratio is 60.33. In terms of profitability, SXTC's ROE is -0.31%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, SXTC is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
SXTC vs TYHT Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SXTC's ROE is -0.31%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, SXTC is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
SXTC vs SIGA Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SIGA's P/E ratio is 10.63. In terms of profitability, SXTC's ROE is -0.31%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, SXTC is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
SXTC vs OGI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas OGI's P/E ratio is -4.96. In terms of profitability, SXTC's ROE is -0.31%, compared to OGI's ROE of -0.07%. Regarding short-term risk, SXTC is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SXTC vs LFCR Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas LFCR's P/E ratio is -4.46. In terms of profitability, SXTC's ROE is -0.31%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, SXTC is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
SXTC vs REPH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas REPH's P/E ratio is -8.04. In terms of profitability, SXTC's ROE is -0.31%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SXTC is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
SXTC vs DERM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas DERM's P/E ratio is -17.38. In terms of profitability, SXTC's ROE is -0.31%, compared to DERM's ROE of -0.36%. Regarding short-term risk, SXTC is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
SXTC vs CRDL Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CRDL's P/E ratio is -5.41. In terms of profitability, SXTC's ROE is -0.31%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, SXTC is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
SXTC vs THTX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas THTX's P/E ratio is -28.83. In terms of profitability, SXTC's ROE is -0.31%, compared to THTX's ROE of +0.17%. Regarding short-term risk, SXTC is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
SXTC vs ASRT Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ASRT's P/E ratio is -7.10. In terms of profitability, SXTC's ROE is -0.31%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, SXTC is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
SXTC vs CPIX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CPIX's P/E ratio is -19.90. In terms of profitability, SXTC's ROE is -0.31%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, SXTC is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
SXTC vs SCTL Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SXTC's ROE is -0.31%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SXTC is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
SXTC vs BGM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas BGM's P/E ratio is -1.01. In terms of profitability, SXTC's ROE is -0.31%, compared to BGM's ROE of -0.07%. Regarding short-term risk, SXTC is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
SXTC vs PROC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PROC's P/E ratio is 1.53. In terms of profitability, SXTC's ROE is -0.31%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SXTC is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
SXTC vs OPTN Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SXTC's ROE is -0.31%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, SXTC is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
SXTC vs ZOM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SXTC's ROE is -0.31%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, SXTC is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
SXTC vs GRVI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SXTC's ROE is -0.31%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, SXTC is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
SXTC vs ZYBT Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, SXTC's ROE is -0.31%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, SXTC is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
SXTC vs TLPH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TLPH's P/E ratio is -4.52. In terms of profitability, SXTC's ROE is -0.31%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, SXTC is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
SXTC vs ZYNE Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SXTC's ROE is -0.31%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SXTC is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
SXTC vs SSIC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SSIC's P/E ratio is 11.93. In terms of profitability, SXTC's ROE is -0.31%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, SXTC is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
SXTC vs VLNS Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SXTC's ROE is -0.31%, compared to VLNS's ROE of N/A. Regarding short-term risk, SXTC is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
SXTC vs DRRX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SXTC's ROE is -0.31%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, SXTC is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
SXTC vs INCR Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas INCR's P/E ratio is -2.23. In terms of profitability, SXTC's ROE is -0.31%, compared to INCR's ROE of -0.09%. Regarding short-term risk, SXTC is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
SXTC vs JUPW Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SXTC's ROE is -0.31%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, SXTC is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
SXTC vs CPHI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CPHI's P/E ratio is -1.72. In terms of profitability, SXTC's ROE is -0.31%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, SXTC is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
SXTC vs QLI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas QLI's P/E ratio is -4.92. In terms of profitability, SXTC's ROE is -0.31%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SXTC is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
SXTC vs HEXO Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SXTC's ROE is -0.31%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SXTC is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
SXTC vs RMTI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas RMTI's P/E ratio is -7.42. In terms of profitability, SXTC's ROE is -0.31%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, SXTC is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
SXTC vs AYTU Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas AYTU's P/E ratio is -1.23. In terms of profitability, SXTC's ROE is -0.31%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, SXTC is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
SXTC vs TXMD Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas TXMD's P/E ratio is 105.96. In terms of profitability, SXTC's ROE is -0.31%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, SXTC is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
SXTC vs CYTH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SXTC's ROE is -0.31%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SXTC is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
SXTC vs EVOK Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SXTC's ROE is -0.31%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, SXTC is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
SXTC vs OPTH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas OPTH's P/E ratio is -17.38. In terms of profitability, SXTC's ROE is -0.31%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, SXTC is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
SXTC vs ACRX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SXTC's ROE is -0.31%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, SXTC is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
SXTC vs BFRIW Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, SXTC's ROE is -0.31%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, SXTC is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
SXTC vs COSM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas COSM's P/E ratio is -0.29. In terms of profitability, SXTC's ROE is -0.31%, compared to COSM's ROE of -0.96%. Regarding short-term risk, SXTC is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
SXTC vs AGRX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SXTC's ROE is -0.31%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SXTC is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
SXTC vs NLTX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SXTC's ROE is -0.31%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, SXTC is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
SXTC vs LCI Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas LCI's P/E ratio is -0.04. In terms of profitability, SXTC's ROE is -0.31%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SXTC is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
SXTC vs ADMP Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SXTC's ROE is -0.31%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SXTC is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
SXTC vs YCBD Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas YCBD's P/E ratio is -1.49. In terms of profitability, SXTC's ROE is -0.31%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, SXTC is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
SXTC vs GELS Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas GELS's P/E ratio is -1.14. In terms of profitability, SXTC's ROE is -0.31%, compared to GELS's ROE of -0.25%. Regarding short-term risk, SXTC is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
SXTC vs MNK Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas MNK's P/E ratio is -0.44. In terms of profitability, SXTC's ROE is -0.31%, compared to MNK's ROE of -0.36%. Regarding short-term risk, SXTC is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
SXTC vs FLGC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SXTC's ROE is -0.31%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, SXTC is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
SXTC vs UPC Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas UPC's P/E ratio is -0.75. In terms of profitability, SXTC's ROE is -0.31%, compared to UPC's ROE of -0.03%. Regarding short-term risk, SXTC is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
SXTC vs SBFM Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SBFM's P/E ratio is -0.20. In terms of profitability, SXTC's ROE is -0.31%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, SXTC is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
SXTC vs PLXP Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PLXP's P/E ratio is -0.22. In terms of profitability, SXTC's ROE is -0.31%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, SXTC is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
SXTC vs SHPH Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SHPH's P/E ratio is -0.20. In terms of profitability, SXTC's ROE is -0.31%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, SXTC is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
SXTC vs ATNX Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas ATNX's P/E ratio is -0.02. In terms of profitability, SXTC's ROE is -0.31%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, SXTC is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
SXTC vs SNOA Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas SNOA's P/E ratio is -1.16. In terms of profitability, SXTC's ROE is -0.31%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, SXTC is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
SXTC vs PROCW Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas PROCW's P/E ratio is N/A. In terms of profitability, SXTC's ROE is -0.31%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, SXTC is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
SXTC vs RDHL Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas RDHL's P/E ratio is 0.12. In terms of profitability, SXTC's ROE is -0.31%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, SXTC is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
SXTC vs YCBD-PA Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, SXTC's ROE is -0.31%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, SXTC is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for SXTC.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
SXTC vs CYTHW Comparison August 2026
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SXTC stands at 1.8M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, SXTC is priced at $3.39 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SXTC currently has a P/E ratio of 1.18, whereas CYTHW's P/E ratio is N/A. In terms of profitability, SXTC's ROE is -0.31%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, SXTC is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for SXTC.Check CYTHW's competition here